RxDoctor Payments Data

Joshua Buck, NP

Family · Johnson City, TNNPI 1205357977

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,985 of the $19,065 with a category attached, or 83.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,065in general payments, 2019–2025

Across 866 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$2K
  • Johnson & Johnson$1K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$793
  • Incyte Corporation$706
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$15,98584%
  • Education$1,7179%
  • Other$1,3637%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis70$2,512
AstraZeneca(2 entities)77$1,568
Johnson & Johnson50$1,030
Merck49$1,015
E.r. Squibb & Sons, L.L.C.53$793
Incyte Corporation29$706
Astellas Pharma US Inc32$703
Pfizer32$697
Daiichi Sankyo Inc.30$641
Bristol Myers Squibb36$614
AVEO Pharmaceuticals, Inc.14$553
Gilead(2 entities)24$540
Amgen22$488
Lilly USA, LLC23$466
Genentech USA, Inc.22$446
Seagen Inc.16$438
GSK24$405
AbbVie25$392
Sanofi17$371
Eisai Inc.17$327
Takeda Pharmaceuticals U.S.A., Inc.14$300
Sanofi-aventis U.S. LLC4$300
Regeneron Healthcare Solutions, Inc.10$277
Exelixis Inc.9$251
Bayer10$186
Ipsen Biopharmaceuticals, Inc8$186
EMD Serono, Inc.8$178
Puma Biotechnology, Inc.9$161
Tersera Therapeutics LLC8$155
Rigel Pharmaceuticals, Inc.7$146
Pharmacyclics LLC, An Abbvie Company7$134
Beigene USA, Inc.6$132
Genmab U.S., Inc.5$117
Array Biopharma Inc5$113
Novo Nordisk13$112
Deciphera Pharmaceuticals Inc.4$108
Biohaven Pharmaceuticals, Inc.7$102
Karyopharm Therapeutics Inc.4$100
Beone Medicines USA, Inc.5$98
Boehringer Ingelheim5$95
Myriad Genetic Laboratories, Inc.5$90
Morphosys, US Inc.3$88
G1 Therapeutics, Inc.4$73
Mirati Therapeutics, Inc.2$66
Caris MPI, Inc.3$60
Geron Corporation3$58
Taiho Oncology, Inc.3$55
Pharmaessentia USA Corporation2$50
Jazz Pharmaceuticals Inc.2$45
Iovance Biotherapeutics, Inc.2$44
Epizyme, Inc.2$41
Apellis Pharmaceuticals, Inc.2$41
Kyowa Kirin, Inc.2$37
Sobi, Inc2$33
Dexcom, Inc.2$33
Agios Pharmaceuticals, Inc.2$31
Celltrion USA Inc.1$29
Foundation Medicine, Inc.1$27
Alnylam Pharmaceuticals Inc.1$26
Acceleron Pharma, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,065 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$218,886
Medicare patients
76
Services billed
9,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$15,807
Febuxostat34$1,381
Letrozole87$1,354
Megestrol Acetate17$975
Dexamethasone26$637
Lidocaine-PrilocaineLidocaine/Prilocaine47$601
Ondansetron OdtOndansetron30$584
Ibandronate Sodium17$507
Potassium Chloride28$415
ValacyclovirValacyclovir Hcl11$396
Prochlorperazine Maleate31$380
Omeprazole39$304
Ondansetron Hcl20$290
Ciprofloxacin Hcl35$279
Oxycodone Hcl16$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$697$15,80723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →